No abstract

No abstract

Peripheral sensory neuropathy treatment is one of the common treatment problems and causes morbidity and mortality in people suffering from that. Although treatment depends on the underlying cause of the condition, nevertheless, in some cases, there is no cure for it, and it requires palliative and symptomatic treatment. In laboratory studies, low-level laser has been effective in the nerves protection and restoration. The aim of this article is to investigate the clinical efficacy of low-level laser on improvement of the peripheral somatosensory neuropathy. Search in the articles published up to 30 October 2015 (full text and abstracts) in databases PubMed (Medline), Cochrane library, Physiotherapy Evidence Database was performed. The studies of low-level laser trials on patients with peripheral neuropathy were carried out and evaluated in terms of the exclusion criteria. There are 35 articles among which 10 articles had the intended and required criteria. 1, 3, and 6 articles study the patients with diabetes, neuropathy caused by trauma, and carpal tunnel syndrome, respectively. In six studies, laser led to a reduction in sensory impairment and improvement of the physiological function of the sensory nerves. In these articles, lasers (Diode, GaAlAs, He-Ne) had wavelength range 660-860 nm, radiation power 20-250 mW, energy density 0.45-70 J/cm. The intervention sessions range was 6-21 times and patient follow-up was 0-6 months. According to the results of these studies, low-level laser therapy can improve sensory function in patients with peripheral somatosensory neuropathy, although little research have not been done, laser treatment regimens are varied and do not recommend a specific treatment protocol. It seems it requires more research to sum up better, particularly in relation to diabetes.

No abstract

Aim: Pain is one of the clinical problems after orofacial surgeries. There have been various studies about the analgesic effect of nonsteroidal antiinflammatory drugs (NSAIDs) in this group of surgeries. In recent years, meloxicam has undergone clinical trials in dentistry. The purpose of this study was to review the efficacy of meloxicam on postoperative pain in dentistry. Materials and methods: The study design was in accordance with the PRISMA guidance. The keywords according to MeSH and related articles were searched in the EBSCO, MEDLINE (via Ovid), PubMed, Science Direct, Scopus, Web of Science and Google Scholar databases. Then eligible randomized clinical trials articles, which released up to December 2017, were thoroughly reviewed. Results: The nine eligible articles were studied. Meloxicam was administered with doses of 7.5, 10 and 15 mg (oral or intramuscular) before or after the third molar extraction. Meloxicam has a similar or significantly better analgesic effect than some of the selective and nonselective NSAIDs and significantly has a better analgesic effect than some of salicylic acids and tramadol. Conclusion: Meloxicam can be considered as an alternative analgesic agent than some NSAIDs, tramadol and salicylic acids in patients who have undergone the third molar extraction.The best way to pain intensity control following orofacial surgeries has not yet been introduced. According to a common rule, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen or their combination are the most prescribed items for of pain intensity control after orofacial surgery 6,7 .Up to now, many studies have been conducted to evaluate the effectiveness of different analgesic drugs, including opioids, corticosteroids, salicylic acids and NSAIDs in dentistry. Generally, selective cyclooxygenase-2 (COX-2) inhibitor NSAIDs may be preferred over their non-selective ones in terms of pain intensity control and a decrease in additional Oral Surgery 13 (2020) 188--196.

Cardiovascular events are the main cause of mortality in chronic kidney disease (CKD) patients. Increased carotid artery intimamedia thickness (C-IMT) is a strong predictor for cardiovascular events. The present study aimed to evaluate the effect of kidney transplantation on C-IMT in CKD patients. Eligible end-stage renal disease (ESRD) patients were evaluated by B-mode ultrasonography regarding C-IMT (mm) and atherosclerotic plaque size (mm 2 ) 1 week before and 6 months after the hemodialysis or kidney transplantation. Also, peak systolic velocity (PSV, cm/s) of carotid artery was accessed with duplex ultrasonography. 38 hemodialysis and 56 kidney transplantation patients were enrolled in the study. The mean age of the patients was 55.1 ± 10.4 years. 32 (34%) cases were female, and the rest were male. The mean of C-IMT before and 6 months after hemodialysistransplantation was 0.71 ± 0.2 -0.71 ± 0.2 mm (p = 0.8) and 0.75 ± 0.2 -0.66 ± 0.2 mm (p = 0.01), respectively. The mean of PSV before and after hemodialysis -transplantation was 58 ± 13.9 -58.3 ± 15.6 cm/s (p = 0.9) and 60.9 ± 12.7 -59.3 ± 12.4 cm/s (p = 0.6), respectively. The mean of atherosclerotic plaque size before and after hemodialysis -transplantation was 64.6 ± 34.3 -50.1 ± 31.2 mm 2 (p = 0.2) and 59.3 ± 31.1 -48.8 ± 30.3 mm 2 (p = 0.4), respectively. After 6 months, kidney transplantation in comparison with hemodialysis was associated with a significant decrease in C-IMT and was not effective on improving the size of atherosclerotic plaque and PSV.

No abstract